ES cell

What is an ES cell

Embryonic stem cells (ES cells) are pluripotent stem cells established from the inner cell mass of an early-stage blastocyst.Pluripotency capable of differentiating into almost all somatic cells and high proliferative capacityis characterized by having. Unlike iPS cells, because they do not go through a process of dedifferentiating mature cells, the stability of their genome and epigenome is considered to be relatively high. In addition, uniform cell banks (MCB/WCB) can be constructed as allogeneic cell lines, and clinical applications are expected through differentiation into a wide range of cells, such as retinal, neural, cardiac, and hematopoetic systems.

representative examples of ES cells

RPE65-independent retinal pigment epithelium cell products (e.g., Rizonicel / Lineage Cell Therapeutics, etc.)

ES cell-derived retinal pigment epithelium (RPE) cell products, such as Rizonicel, are cell therapies targeting age-related macular degeneration and geographic atrophy (GA).local transplantation into the eyeball, which is an immune-privileged siteare attracting attention as development models that are less susceptible to the effects of systemic immune rejection.

ESC-derived cardiac progenitor cells / cardiac spheroids (e.g., ESC-derived Cardiac Progenitors)

ES cell-derived cardiomyocyte progenitor cells and three-dimensional myocardial spheroids are cell therapy approaches aimed at myocardial regeneration for severe heart failure.Electrophysiological integration with host myocardium (Syncytium formation)While being anticipated, non-clinical evaluation of arrhythmogenic risk is important.

Embryonic stem cell-derived oligodendrocyte progenitor cells (e.g., AST-OPC1 / Lineage Cell Therapeutics, etc.)

Embryonic stem cell-derived oligodendrocyte progenitor cells (OPCs) represent a central nervous system regeneration approach targeting conditions such as spinal cord injury (SCI).Recovery of neurological function through remyelinationwhile being expected, important safety evaluations are required, such as unintended proliferation after transplantation and effects on tissues.

Important challenges in ES cell development

Risk of in vivo teratoma formation due to trace residual undifferentiated ES cells (positive for Oct4/Nanog/SSEA-4, etc.)

Because ES cells possess high pluripotency and self-renewal capacity, if undifferentiated ES cells remain in the product after directed differentiation, they may form teratomas consisting of tissues derived from all three germ layers within the body.To detect trace amounts of undifferentiated cells with high precision and evaluate the risk of tumorigenesisis an important issue.

Strong alloimmune rejection and inhibition of long-term engraftment caused by allogeneic fertilized egg-derived cells

Because ES cells are derived from fertilized eggs of a third party, if their HLA types do not match those of the patient, immune rejection may occur.alloimmune responses by host T cells and NK cellsA major challenge is that the administered cells are eliminated by the host, which inhibits long-term persistence.

Difficulty in ensuring lot-to-lot consistency due to the complexity of the differentiation induction process and the contamination of off-target lineage fractions

Inducing differentiation from ES cells into target cells requires a multi-step process, which may result in the contamination of immature progenitor cells or unintended cell fractions.managing differentiation maturity and impurity profiles to ensure lot-to-lot consistencyis an important issue.

Non-clinical evaluation required for ES cell development

Rating 1: "Maximum elimination of teratoma formation risk through high-sensitivity in vitro undifferentiated cell detection and ultra-long-term in vivo local transplantation evaluation in severely immunodeficient animals"

To evaluate the tumorigenicity caused by the residual undifferentiated ES cells, undifferentiated cells in the final product are detected with high sensitivity, and long-term transplantation studies are conducted in severe immunodeficient animals.Combining in vitro detection and long-term in vivo evaluationAnd then, we will comprehensively confirm the teratoma formation risk and tissue safety.

Rating 2: "Humanized Mouse Allo-rejection & In Vivo Biodistribution Analysis" evaluating alloimmune rejection and in vivo pharmacokinetics

To evaluate the immune rejection, in vivo migration, and engraftment of allogeneic ES cell-derived products, studies using humanized mice are important.Combining in vivo imaging and organ-specific ddPCRThen, we quantitatively evaluate cell survival, distribution, ectopic engraftment, and other parameters.

Rating 3: "Single-Cell RNA-seq & Spatial Transcriptomics Analysis" for visualizing differentiation maturity and cellular impurities at the single-cell level

To evaluate the differentiation maturity and cell diversity of ES cell-derived products, analysis at the single-cell level is important.Visualization and identification of trace amounts of immature cells and unintended cell fractions by scRNA-seq and Spatial Transcriptomics, and is utilized for evaluating the degree of differentiation into target cells, impurity profiles, and lot-to-lot consistency.

Rating 4: "3D organoids/electrophysiological function & disease pathology model in vivo drug efficacy evaluation" validating tissue compatibility and physiological functions

To evaluate whether ES cell-derived products not only survive in vivo, but also functionally integrate with host tissue and exert therapeutic effects.combining 3D organoids or electrophysiological analysis with disease animal modelsThen, we will comprehensively verify the histocompatibility and functional efficacy.

Key points when choosing a contract research organization (CRO) for non-clinical studies

ES cells have the potential to differentiate into a wide range of cell types and are expected to be applied in regenerative medicine. On the other hand, there are challenges such as tumorigenicity, immune rejection, differentiation maturity, and functional integration. Selecting a CRO capable of conducting highly sensitive safety evaluations and multifaceted non-clinical studies is crucial for development success. Moving forward, a system capable of comprehensively verifying quality, safety, and efficacy will be required.